Anteris Technologies Global Corp. (AVR)
Nasdaq · Healthcare · Medical Devices
$7.55−2.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $736M
- 52-week range
- $3.30 – $11.06
- 52-week change
- +76.43%
- EPS (trailing)
- −$1.91
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $1.9M (−29.23%)
- Net income
- −$94.1M
- Operating margin
- −4908.2%
- Diluted EPS
- −$2.55
- Free cash flow
- −$79.8M
From the company’s annual report on SEC EDGAR.
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Headquarters: Toowong, Australia · 174 employees · anteristech.com